On May 15, 2014, Hearn Jay Cho, M.D., Ph.D., an assistant professor of medicine, hematology, and medical oncology at Mount Sinai Hospital, discussed current immunotherapy treatment options for patients with multiple myeloma, and how close we are to making these treatments available to more patients.
Dr. Cho’s laboratory is investigating novel therapies targeting the type I Melanoma Antigen GEnes (MAGE) CT7 (MAGE-C1) and MAGE-A3 in multiple myeloma. Dr. Cho received his undergraduate degree in molecular biology from Princeton University and graduated from the Tri-Institutional MD-PhD Program of Cornell University Medical College with a doctoral degree in immunology. He was a resident in the Clinical Investigator Track in the Department of Internal Medicine at the University of California, San Diego, where he also did a postdoctoral research fellowship in immunology. He completed his clinical fellowship in hematology and medical oncology at The New York-Presbyterian Hospital/Weill Cornell Medical College and was a visiting research fellow at The Rockefeller University.